Skip to main content
Premium Trial:

Request an Annual Quote

BAC HD Scan

Premium
CombiMatrix Molecular Diagnostics announced this week that it has launched its BAC HD Scan test, after having completed clinical validation of the diagnostic.
 
The company said the high-density constitutional array genetic test is based on its Bacterial Artificial Chromosome array technology, and is comprised of 2,437 unique validated loci obtained through the company's partnership with Toronto-based Center of Applied Genomics.
 
“The new test is designed to interrogate specific genes and genomic regions associated with over 125 known genetic disorders while enabling screening for unexpected abnormalities with an industry-best average resolution of 432 kb across the entire genome,” the company said in a statement. The array also incorporates the probe content of CombiMatrix's recently launched ATScan for Autism Spectrum Disorder. 
 
"One of the major advantages of our testing is that it enables the evaluation of thousands of genomic regions simultaneously while requiring no prior knowledge of what kind of abnormalities may be present in a patient — essentially, it can act as a screen for genomic abnormalities,” Mercedes Gorre, CombiMatrix Molecular Diagnostics VP of scientific affairs, said in a statement.
 
The list of 125 disorders can be reviewed here

Filed under

The Scan

New Study Highlights Role of Genetics in ADHD

Researchers report in Nature Genetics on differences in genetic architecture between ADHD affecting children versus ADHD that persists into adulthood or is diagnosed in adults.

Study Highlights Pitfall of Large Gene Panels in Clinical Genomic Analysis

An analysis in Genetics in Medicine finds that as gene panels get larger, there is an increased chance of uncovering benign candidate variants.

Single-Cell Atlas of Drosophila Embryogenesis

A new paper in Science presents a single-cell atlas of fruit fly embryonic development over time.

Phage Cocktail Holds Promise for IBD

Researchers uncovered a combination phage therapy that targets Klebsiella pneumonia strains among individuals experiencing inflammatory bowel disease flare ups, as they report in Cell.